Evidence map›Paper›PMID 38995514›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2025

Clinical characteristics and prognosis of pancreatitis associated with immune checkpoint inhibitors.

Junzi Zhang, Xianzhuo Jiang, Ning Liu, Zhaoxue Qi, Xuguang Mi, Yanqiu Fang, Wenqi Zhang, Zhen Yang, Wenjie Ou, Xiuying Lin and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Type 3 Autoimmune Pancreatitis: What Do We Know So Far?Digestive diseases and sciences · 2026
    Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Junzi ZhangChangchun University of Chinese Medicine, Changchun, Jilin, China.
Xianzhuo JiangDepartment of Tumor Comprehensive Therapy, Jilin Provincial People's Hospital, Changchun, Jilin, China.
Ning LiuGeneral Surgery of the First Clinical Hospital of Jilin Academy of Chinese Medicine Sciences, Changchun, Jilin, China.
Zhaoxue QiDepartment of Secretory Metabolism, The First Hospital of Jilin University, Changchun, Jilin, China.
Xuguang MiDepartment of Central Laboratory, Jilin Provincial People's Hospital, Changchun, Jilin, China.
Yanqiu FangDepartment of Tumor Comprehensive Therapy, Jilin Provincial People's Hospital, Changchun, Jilin, China.
Wenqi ZhangChangchun University of Chinese Medicine, Changchun, Jilin, China.
Zhen YangChangchun University of Chinese Medicine, Changchun, Jilin, China.
Wenjie OuChangchun University of Chinese Medicine, Changchun, Jilin, China.
Xiuying LinDepartment of Tumor Comprehensive Therapy, Jilin Provincial People's Hospital, Changchun, Jilin, China.
Junjie HouDepartment of Tumor Comprehensive Therapy, Jilin Provincial People's Hospital, Changchun, Jilin, China. houjunjie1979@163.com.ORCID http://orcid.org/0000-0003-2195-771X

Funding

Jilin Province health science and technology ability improvement project 2023LC043
6 · The paper itself

Abstract

BACKGROUND AND

objectiveImmune checkpoint inhibitors (ICIs) have shown remarkable efficacy against various cancers in clinical practice. However, ICIs can cause immune checkpoint inhibitor-associated pancreatic injury, often leading to drug withdrawal, and then patients must go to specialized treatment. The patients, their primary tumors are sensitive to ICIs therapy, may experience treatment delays due to such adverse reactions. Therefore, there is a need for systematic clinical researches on immune-related pancreatic toxicity to provide a clinical basis for its prevention and treatment.

methodsThis study involved the collection of data from patients treated with ICIs and addressed pancreatic injury with preemptive treatment before continuing ICIs therapy. Then, we also statistically analyzed the incidence of pancreatic injury in patients with different courses and combined treatment, and the success rate of rechallenge treatment.

resultsThe study included 62 patients, with 33.9% (21/62) experiencing varying degrees of pancreatic injury. Patients with pancreatic injury, 10 cases evolved into pancreatitis, representing 47.6% (10/21) in the pancreatic injury subgroup and 16.1% (10/62) of the total patient cohort. Preemptive treatment was administered to 47.6% (10/21) of patients with pancreatitis, the effective rate was 100%. Among these patients, 70% (7/10) underwent successful rechallenge with ICIs. The occurrence of pancreatic injury was positively correlated with the treatment duration (P < 0.05) but showed no significant correlation with combination therapies (P > 0.05).

conclusionThe likelihood of pancreatic injury increased with longer treatment durations with ICIs; no significant association was found between the incidence of ICIs-related pancreatic damage and combination therapies. Preemptive treatment for immune-related pancreatitis is feasible, allowing some patients to successfully undergo rechallenge with ICIs therapy.

Indexed as

Immune Checkpoint InhibitorsNeoplasmsPancreatitisAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesImmune Checkpoint InhibitorsImmune checkpoint-associated pancreatitisImmune checkpoint inhibitorsImmune-related adverse eventsImmunotherapyMalignant tumor treatment

Identifiers

PMID38995514

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.